Healthy
Conditions
Brief summary
The purpose of this study to Compare the safety and pharmacokinetics between co-administration and fixed dose combination of DWC20155 and DWC20156 in healthy subjects
Interventions
DRUGDWJ1366 Tab.
Sponsors
Daewoong Pharmaceutical Co. LTD.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* BMI ≥ 18.5 and ≤ 27.0 kg/m2. * No clinically significant findings * Age 19-55 years at screening
Exclusion criteria
* Who has allergy to investigational product
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Plasma Concentration (Cmax) | 0-24 hours |
| Area under the plasma concentration versus time curve (AUC) | 0-24 hours |
Countries
South Korea
Outcome results
None listed